WO1993025709A1 - Preparation of nucleic acids - Google Patents

Preparation of nucleic acids Download PDF

Info

Publication number
WO1993025709A1
WO1993025709A1 PCT/GB1993/001223 GB9301223W WO9325709A1 WO 1993025709 A1 WO1993025709 A1 WO 1993025709A1 GB 9301223 W GB9301223 W GB 9301223W WO 9325709 A1 WO9325709 A1 WO 9325709A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
complementary
probe
nucleic acid
oligonucleotides
Prior art date
Application number
PCT/GB1993/001223
Other languages
French (fr)
Inventor
Trevor Leonard Hawkins
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to AU43440/93A priority Critical patent/AU4344093A/en
Publication of WO1993025709A1 publication Critical patent/WO1993025709A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/0099Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00Heating or cooling apparatus; Heat insulating devices
    • B01L7/52Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/0098Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/005Beads
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00722Nucleotides
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N35/1081Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane
    • G01N35/109Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices characterised by the means for relatively moving the transfer device and the containers in an horizontal plane with two horizontal degrees of freedom

Definitions

  • This invention relates to the preparation of nucleic acids and concerns magnetic particles and their use in the preparation of nucleic acids.
  • M13 phage is used to obtain single stranded DNA for sequencing templates.
  • the traditional methods for M13 DNA purification such as polyethylene glycol (PEG)/phenol procedures (Bankier et al . , [1988], in Wu, R. [ed.] , Methods Enz. 155, 52-93) allow microgram quantities of template to be produced from illilitre volumes.
  • thermally cycled sequencing procedures utilising Taq polymerase (Craxton, [1991], Methods: A Companion to Methods in Enzymology 3_, 20-26) only require 200-500ng of - template DNA per reaction. Therefore traditional methods produce an excess of template for most purposes, which wastes both time and money.
  • the invention provides a composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non-complementary to the sequence under investigation.
  • the invention provides a method of producing the composition defined above, comprising attaching magnetic particles to an oligonucleotide comprising a complementary probe sequence and further comprising a non-complementary sequence.
  • the magnetic particles take the form of beads. Typically these are about 1-5um in diameter. Suitable magnetic beads are commercially available. For instance, they may be obtained from Dynal or, more preferably, from Promega. Those from Promega are found particularly suitable because they have a pitted surface and therefore a higher surface area, which allows greater ' amounts of oligonucleotides to be carried by the bead.
  • 'Oligonucleotides' as used herein includes both synthetic and native DNA and RNA sequences of any length.
  • the oligonucleotide is preferably single stranded DNA and, conveniently, the complementary probe sequence is substantially 25-45 bases long.
  • the non-complementary sequence is generally 5-15 bases in length, typically about 9 bases long.
  • the non-complementary sequence of the oligonucleotide acts as a 'linker' joining the complementary probe sequence to the magnetic bead.
  • the probe sequence may be attached by either end to the linker oligonucleotide.
  • the oligonucleotide may be attached to the magnetic bead by conventional techniques.
  • the linker oligonucleotide may conveniently be biotinylated at the end region distal to the end joined to the complementary probe sequence, allowing for ready attachment to streptavidin-coated magnetic beads.
  • Other attachment techniques are known to those skilled in the art.
  • the probe sequence can, of course, be selected so as to be complementary to any nucleic acid sequence of interest such that, for example, the sequence of interest may be separated from a complex sample by being bound by the magnetic bead/probe and then separated from the rest of the sample by magnetic attraction.
  • the invention provides a method of separating a nucleic acid sequence from a sample comprising: contacting a complex sample possibly including the sequence of interest with the composition of the present invention; allowing the sequence of interest, if present, to associate with the composition by means of hybridisation with the complementary probe sequence; and separating the composition and any bound nucleic acid sequences from the rest of the sample by magnetic attraction.
  • the complementary probe sequence comprises an oligonucleotide complementary to the sequence of M13.
  • the invention therefore provides a method of preparing template DNA for sequencing.
  • the probe sequence is complementary to a region upstream from the M13 -21 universal primer site.
  • the arrangement described above can confer a number of advantages over prior art methods of purifying nucleic acids.
  • the use of a non-complementary linker sequence reduces the likelihood of steric hindrance between the comparatively bulky magnetic bead and the "target" DNA hybridised to the probe. This allows beads prepared in accordance with the invention to bind far more 'target' DNA than possible hitherto.
  • probe sequences may become separated from magnetic beads of the prior art by shearing and may act as unwanted "false" primers in subsequent sequencing reactions.
  • the non-complementary linker oligonucleotide of the invention ensures that, should the oligonucleotides become separated from the beads, they are far less likely to be able to prime chain-extension reactions. It is a preferred feature therefore that the linker sequence should be at the 3' end of the complementary probe sequence, as this further reduces the risk of non-specific priming.
  • the invention provides a method of preparing a DNA sequence of interest from a complex sample comprising: causing lysis of DNA-containing entities by the action of heat in the presence of a suitable detergent; adding magnetic particles attached to a probe complementary to at least part of the sequence of interest together with hybridisation buffer containing a polymer to cause an increase in the effective nucleic acid concentration; allowing the sequence of interest to hybridise to the complementary probe and then separating the particle/probe complex and any sequences hybridised thereto from the rest of the sample by magnetic attraction.
  • any magnetic particles to which are attached an appropriate probe are suitable for performing the method defined above, including those already known in the art. However, it is preferred that the particles used are those according to the present invention.
  • a suitable detergent is SDS.
  • the DNA-containing entities are typically phages.
  • a suitable polymer is PEG.
  • the use of a polymer to increase the effective concentration of nucleic acid allows smaller volumes of reagents to be used than previously, which in turn enables the method to be performed in a microtitre plate or tray. Similarly, the method is particularly simple and efficient as it employs a target sequence-specific purification step.
  • the invention provides a method of preparing DNA by means of a sequence-specific purification step, capable of being performed in a microtitre plate.
  • the ability to perform the method in a microtitre plate makes the method of the invention particularly amenable to automation.
  • Suitable automated apparatus for performing the method of the invention is described in GB9212164.9 (co-pending Application No PCT/GB93/ ).
  • Figure 1 shows the base sequence of a suitable probe/linker oligonucleotide
  • Figure 2 shows a photograph of gel electrophoresis performed on DNA prepared by the method of the invention.
  • Figure 3 shows a portion of sequencing trace
  • the invention involves an oligonucleotide probe which has been synthesised with a biotin group at the 3' end.
  • the probe is designed to be complementary to a region upstream from the M13 -21 Universal priming site.
  • single plaques may be grown up in culture, the cells harvested and the supernatant collected and lysed to yield free single strands.
  • the bead/probe complex is then added, and the probe allowed to anneal to the target DNA. Once bound, the bead/probe/template complex can be separated from the rest of the sample using magnetic attraction and then washed.
  • the template may then be freed from the bead/probe complex by heating.
  • the procedure is simple and fast. All the post-growth steps can be carried out in microtitre plates with no centrifugation or ethanol precipitations required. In this example, 250 random M13 sub-clones were prepared and se ⁇ uenced using the method outlined below.
  • the amount of template recovered depends directly on the design of the probe.
  • the probe must be specific to the target but must not act as a secondary sequencing primer if free probe is left in solution. Consequently, the probe is 41bp in length and binds to a region upstream from the M13 -21 Universal primer site.
  • the probe has a run of several 'A's at the 3' end together with the biotin group. This acts as a linker arm to prevent steric hindrance between the large streptavidin-coated beads and the binding of the probe to the target. Also the high degree of non-complementarity at the 3 * end would prevent the free probe from acting as a sequencing primer should it shear from the beads.
  • the design of the probe is shown in Figure 1, ('B' represents Biotin).
  • the probe THM13.3 was synthesised on an ABI 380B DNA synthesiser on a 1uMole scale. Biotin phosphoramidite was obtained frm Amersham U.K. The sequence of the probe was: 5' TAT CGG CCT CAG GAA GAT CGC ACT CCA GCC AGC AAA AAA Biotin A 3' (Seq ID No. 1). Following cleavage from the column, the oligonucleotide was deprotected in ammonia at 55°C overnight. A NAP-10 column was used to purify the crude oligonucleotide. Probe/streptavidin bead linkage
  • Promega nucleotide quality beads were used in this example. 1.2ml of Promega beads were used per 12 samples. The beads were washed in 0.1M NaCl three times using a neodymium-iron-boron permanent magnet to separate the beads from the washing solution. 200ul 0.1M NaCl and 1On ol THM13.3 oligonucleotide were then added to 1.2ml( 1.2mg) dry beads and incubated at room temperature for 10 minutes. The beads were then washed 10 times in 0.1M NaCl to remove unbound oligonucleotide. Bead/probe complex was finally taken up in 1.2ml water. Beads may be bound to probe in bulk and stored in storage buffer at 4°C.
  • Random M13 sub-clones with 1-2kb inserts were grown up in 2ml 2xTy medium (16g bacto tryptone, 10g yeast extract, 5g NaCl in 11 water) for 5 hours at 37°C. Cells were spun down at 14,000g for 5 minutes and the supernatant transferred to microtitre plates. 400ul supernatant was used from each sample, using two wells, each containing 200ul supernatant (Falcon 3911 MicroTest Flexible Assay Plate. )
  • the microtitre plate was removed from the cycler and placed on a Dynal MPC-96 magnetic separator. After 30 seconds the supernatant was aspirated, 100ul wash buffer (0.1X SSC) were added to each well and the beads were moved through the wash buffer by repositioning the plate over the magnetic separator three times at intervals of five seconds. This step was repeated a total of three times. Finally, the beads were eluted in 10ul water; using the magnet, beads may be dispersed into this small volume.
  • 100ul wash buffer 0.1X SSC
  • the templates were released from the probe by heating the plate to 80 C for 3 minutes. After heating, the beads were concentrated using the magnet and the supernatant was removed to a fresh microtitre plate. Due to evaporation the final total volume was approximately 8ul from each well, or approximately 16ul per DNA template sample.
  • FIG. 2 The efficacy of the technique is illustrated by Figure 2.
  • Four random M13 subclones were grown as described. The cells were harvested and the supernatant (1200ul) was split three ways to provide three identical samples. A, B and C (400ul each). For each sub clone. Sample A was prepared using the method outlined previously. Sample B was prepared as outlined but leaving out the hybridisation buffer (20% PEG/2.5M NaCl). Sample C was prepared as outlined but using magnetic beads without a probe attached. The samples were then subjected to agarose gel electrophoresis. This showed that when the PEG is removed there is a dramatic reduction in yield, as expected. When beads are used without probe attached the resulting yield is zero. The difference between this control and the method of Alderton et al., (1992), is that in sample C the phage are lysed before addition of PEG.
  • beads may be re-used as outlined below.
  • Beads were collected and pooled in a 1.5ml eppendorf tube. The supernatant was removed and the beads were resuspended in 1ml reuse buffer (0.15M NaOH, 0.001% Tween 20) for 1 minute. The supernatant was removed and the procedure repeated. Finally the beads were washed once in storage buffer and taken up in half the original volume of storage buffer (PBS pH 7.5, 0.1% BSA). Beads were then stored at 4°C.
  • a preferred feature of the method of preparing DNA is to bring about magnetic attraction for the magnetic beads by the use of a "dot magnet".
  • a typical microtitre assay plate generally 130 mm by 85 mm
  • the dot magnet comprises an array of 96 such rare earth magnets which are positioned in a matrix 8 x 12 and are separated by about 9mm from each nearest neighbour (ie. substantially the same spacing as that between the wells of a microtitre plate) thus when the sides of the dot magnet are aligned with the sides of a typical microtitre plate, each rare earth magnet is positioned beneath a well in the microtitre plate.
  • MOLECULE TYPE DNA (genomic)
  • HYPOTHETICAL NO
  • ANTI-SENSE NO

Abstract

Disclosed is a composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non-complementary to the sequence under investigation. Also disclosed is a method of purifying a nucleic acid using the composition of the invention and a method of preparing a nucleic acid.

Description

Title Preparation of Nucleic Acids
Field of the Invention
This invention relates to the preparation of nucleic acids and concerns magnetic particles and their use in the preparation of nucleic acids.
Background of the Invention
Currently, a number of large scale DNA sequencing projects are under way. One of the rate-limiting steps in the generation of sequence data is the preparation of high purity DNA templates.
Typically, M13 phage is used to obtain single stranded DNA for sequencing templates. The traditional methods for M13 DNA purification, such as polyethylene glycol (PEG)/phenol procedures (Bankier et al . , [1988], in Wu, R. [ed.] , Methods Enz. 155, 52-93) allow microgram quantities of template to be produced from illilitre volumes. However, thermally cycled sequencing procedures utilising Taq polymerase (Craxton, [1991], Methods: A Companion to Methods in Enzymology 3_, 20-26) only require 200-500ng of - template DNA per reaction. Therefore traditional methods produce an excess of template for most purposes, which wastes both time and money.
Some alternative methods of preparing template DNA have been described which employ a microtitre-scale format, and thereby reduce waste. For example, one method uses specialised filtration steps (Kristensen et al., [1987], Nucleic Acids Research 1_5_, 5507-5516), whilst another (Smith et al. , [1990], Journal of DNA Sequencing and Mapping λ_, 73-78) requires the use of PEG/sodium dodecyl sulphate (SDS) with multiple centrifugation steps. Thus these alternative techniques are somewhat cumbersome and impractical.
More recently, a protocol has been described (Alderton et al., [1992], Analytical Biochemistry 152, 304-307) which utilises magnetic particles together with PEG-phage aggregation. A somewhat similar method is disclosed in WO90/06045. This outlines a method of preparing DNA using magnetic beads coated with oligonucleotides, which serve as hybridisation probes, to form a magnetic bead/probe complex. The magnetic beads and any bound nucleic acids can then be magnetically separated from the rest of the sample. However, further improvements in this technology are possible as disclosed below.
Summary of Invention
In one aspect the invention provides a composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non-complementary to the sequence under investigation.
In another aspect, the invention provides a method of producing the composition defined above, comprising attaching magnetic particles to an oligonucleotide comprising a complementary probe sequence and further comprising a non-complementary sequence.
Conveniently, the magnetic particles take the form of beads. Typically these are about 1-5um in diameter. Suitable magnetic beads are commercially available. For instance, they may be obtained from Dynal or, more preferably, from Promega. Those from Promega are found particularly suitable because they have a pitted surface and therefore a higher surface area, which allows greater 'amounts of oligonucleotides to be carried by the bead.
'Oligonucleotides' as used herein includes both synthetic and native DNA and RNA sequences of any length. However, the oligonucleotide is preferably single stranded DNA and, conveniently, the complementary probe sequence is substantially 25-45 bases long. The non-complementary sequence is generally 5-15 bases in length, typically about 9 bases long.
Preferably, the non-complementary sequence of the oligonucleotide acts as a 'linker' joining the complementary probe sequence to the magnetic bead. The probe sequence may be attached by either end to the linker oligonucleotide.
The oligonucleotide may be attached to the magnetic bead by conventional techniques. For example, the linker oligonucleotide may conveniently be biotinylated at the end region distal to the end joined to the complementary probe sequence, allowing for ready attachment to streptavidin-coated magnetic beads. Other attachment techniques are known to those skilled in the art. The probe sequence can, of course, be selected so as to be complementary to any nucleic acid sequence of interest such that, for example, the sequence of interest may be separated from a complex sample by being bound by the magnetic bead/probe and then separated from the rest of the sample by magnetic attraction.
Thus in another aspect the invention provides a method of separating a nucleic acid sequence from a sample comprising: contacting a complex sample possibly including the sequence of interest with the composition of the present invention; allowing the sequence of interest, if present, to associate with the composition by means of hybridisation with the complementary probe sequence; and separating the composition and any bound nucleic acid sequences from the rest of the sample by magnetic attraction.
Typically the complementary probe sequence comprises an oligonucleotide complementary to the sequence of M13. In a preferred arrangement the invention therefore provides a method of preparing template DNA for sequencing.
Generally the probe sequence is complementary to a region upstream from the M13 -21 universal primer site.
The arrangement described above can confer a number of advantages over prior art methods of purifying nucleic acids. The use of a non-complementary linker sequence reduces the likelihood of steric hindrance between the comparatively bulky magnetic bead and the "target" DNA hybridised to the probe. This allows beads prepared in accordance with the invention to bind far more 'target' DNA than possible hitherto. Furthermore, when preparing DNA for sequencing reactions, probe sequences may become separated from magnetic beads of the prior art by shearing and may act as unwanted "false" primers in subsequent sequencing reactions. However, the non-complementary linker oligonucleotide of the invention ensures that, should the oligonucleotides become separated from the beads, they are far less likely to be able to prime chain-extension reactions. It is a preferred feature therefore that the linker sequence should be at the 3' end of the complementary probe sequence, as this further reduces the risk of non-specific priming.
Conventional methods of preparing template DNA from M13 typically involve aggregation of phage particles at room temperature by the use of PEG/NaCl solutions (typically 20% PEG/2.5M NaCl), followed by lysis with SDS to release DNA, which is then bound to the magnetic bead/probe complex. However, it has now been found that advantages accrue from a novel DNA preparation protocol in which M13 particles are first lysed by the action of heat in the presence of a suitable detergent such as SDS. Subsequently, probe/bead complex is added, together with hybridisation buffer containing a suitable polymer such as PEG. Whereas in conventional methods PEG is used to bring about aggregation of the phage particles, in the novel method of the invention it is added after phage lysis to effectively increase the concentration of the target DNA by excluding nucleic acids from the volume taken up by the polymer (Amasino et al., [1992], Analytical Biochemistry 201, 166-169).
Thus in another aspect the invention provides a method of preparing a DNA sequence of interest from a complex sample comprising: causing lysis of DNA-containing entities by the action of heat in the presence of a suitable detergent; adding magnetic particles attached to a probe complementary to at least part of the sequence of interest together with hybridisation buffer containing a polymer to cause an increase in the effective nucleic acid concentration; allowing the sequence of interest to hybridise to the complementary probe and then separating the particle/probe complex and any sequences hybridised thereto from the rest of the sample by magnetic attraction.
Any magnetic particles to which are attached an appropriate probe are suitable for performing the method defined above, including those already known in the art. However, it is preferred that the particles used are those according to the present invention.
A suitable detergent is SDS.
The DNA-containing entities are typically phages.
A suitable polymer is PEG. The use of a polymer to increase the effective concentration of nucleic acid allows smaller volumes of reagents to be used than previously, which in turn enables the method to be performed in a microtitre plate or tray. Similarly, the method is particularly simple and efficient as it employs a target sequence-specific purification step.
Thus the invention provides a method of preparing DNA by means of a sequence-specific purification step, capable of being performed in a microtitre plate. The ability to perform the method in a microtitre plate makes the method of the invention particularly amenable to automation. Suitable automated apparatus for performing the method of the invention is described in GB9212164.9 (co-pending Application No PCT/GB93/ ).
The various aspects of the invention may be better understood by reference to the following illustrative example and drawings in which:
Figure 1 shows the base sequence of a suitable probe/linker oligonucleotide;
Figure 2 shows a photograph of gel electrophoresis performed on DNA prepared by the method of the invention; and
Figure 3 shows a portion of sequencing trace
Example
In this particular example, the invention involves an oligonucleotide probe which has been synthesised with a biotin group at the 3' end. The probe is designed to be complementary to a region upstream from the M13 -21 Universal priming site.
In general, single plaques may be grown up in culture, the cells harvested and the supernatant collected and lysed to yield free single strands. The bead/probe complex is then added, and the probe allowed to anneal to the target DNA. Once bound, the bead/probe/template complex can be separated from the rest of the sample using magnetic attraction and then washed. The template may then be freed from the bead/probe complex by heating. The procedure is simple and fast. All the post-growth steps can be carried out in microtitre plates with no centrifugation or ethanol precipitations required. In this example, 250 random M13 sub-clones were prepared and seσuenced using the method outlined below.
Probe Design
The amount of template recovered depends directly on the design of the probe. The probe must be specific to the target but must not act as a secondary sequencing primer if free probe is left in solution. Consequently, the probe is 41bp in length and binds to a region upstream from the M13 -21 Universal primer site. The probe has a run of several 'A's at the 3' end together with the biotin group. This acts as a linker arm to prevent steric hindrance between the large streptavidin-coated beads and the binding of the probe to the target. Also the high degree of non-complementarity at the 3 * end would prevent the free probe from acting as a sequencing primer should it shear from the beads. The design of the probe is shown in Figure 1, ('B' represents Biotin).
The probe THM13.3 was synthesised on an ABI 380B DNA synthesiser on a 1uMole scale. Biotin phosphoramidite was obtained frm Amersham U.K. The sequence of the probe was: 5' TAT CGG CCT CAG GAA GAT CGC ACT CCA GCC AGC AAA AAA Biotin A 3' (Seq ID No. 1). Following cleavage from the column, the oligonucleotide was deprotected in ammonia at 55°C overnight. A NAP-10 column was used to purify the crude oligonucleotide. Probe/streptavidin bead linkage
Promega nucleotide quality beads were used in this example. 1.2ml of Promega beads were used per 12 samples. The beads were washed in 0.1M NaCl three times using a neodymium-iron-boron permanent magnet to separate the beads from the washing solution. 200ul 0.1M NaCl and 1On ol THM13.3 oligonucleotide were then added to 1.2ml( 1.2mg) dry beads and incubated at room temperature for 10 minutes. The beads were then washed 10 times in 0.1M NaCl to remove unbound oligonucleotide. Bead/probe complex was finally taken up in 1.2ml water. Beads may be bound to probe in bulk and stored in storage buffer at 4°C.
M13 Sub-clones
Random M13 sub-clones with 1-2kb inserts were grown up in 2ml 2xTy medium (16g bacto tryptone, 10g yeast extract, 5g NaCl in 11 water) for 5 hours at 37°C. Cells were spun down at 14,000g for 5 minutes and the supernatant transferred to microtitre plates. 400ul supernatant was used from each sample, using two wells, each containing 200ul supernatant (Falcon 3911 MicroTest Flexible Assay Plate. )
Lysis
Prior to addition of supernatant, 10ul of 15% SDS was added to each well using an Eppendorf multidispensing pipette. Phages were lysed by heating the microtitre plate to 70 C for 10 minutes on a Techne PHC-3 cycler
Annealing 20ul of hybridisation buffer (20% PEG 8000/2.5M NaCl) was added to each well with a multidispensing pipette; no mixing is required so the same tip may be used for all wells. Also, 20ul bead/probe complex were added to each well, and the dish was incubated at 45°C for 30 minutes.
Wash Steps
The microtitre plate was removed from the cycler and placed on a Dynal MPC-96 magnetic separator. After 30 seconds the supernatant was aspirated, 100ul wash buffer (0.1X SSC) were added to each well and the beads were moved through the wash buffer by repositioning the plate over the magnetic separator three times at intervals of five seconds. This step was repeated a total of three times. Finally, the beads were eluted in 10ul water; using the magnet, beads may be dispersed into this small volume.
Denaturation
The templates were released from the probe by heating the plate to 80 C for 3 minutes. After heating, the beads were concentrated using the magnet and the supernatant was removed to a fresh microtitre plate. Due to evaporation the final total volume was approximately 8ul from each well, or approximately 16ul per DNA template sample.
The efficacy of the technique is illustrated by Figure 2. Four random M13 subclones were grown as described. The cells were harvested and the supernatant (1200ul) was split three ways to provide three identical samples. A, B and C (400ul each). For each sub clone. Sample A was prepared using the method outlined previously. Sample B was prepared as outlined but leaving out the hybridisation buffer (20% PEG/2.5M NaCl). Sample C was prepared as outlined but using magnetic beads without a probe attached. The samples were then subjected to agarose gel electrophoresis. This showed that when the PEG is removed there is a dramatic reduction in yield, as expected. When beads are used without probe attached the resulting yield is zero. The difference between this control and the method of Alderton et al., (1992), is that in sample C the phage are lysed before addition of PEG.
Sequencing Results
Once the templates have been purified, as described above, it is possible to immediately perform the sequencing reactions as pre-reaction mixes can be made up and dispensed in advance. The ABI Taq dye primer kit reagents were used. The total volume after recovery of the template from the probe varies from 14-16ul. From this, 2ul has been used in the A/C reactions and 4ul in the G/T reactions. The volume variability does not reduce the quality of the sequence data. All samples were sequenced using the M13 -21 universal primer and Taq polymerase. The reactions were cycled on a Techne PHC-3 dry cycler, each sample being covered with mineral oil. The reaction products were analysed on an ABI 373A DNA sequencer.
In this study, 250 clones taken from the C. elegans cosmids ZK507, ZK512 and K01B6 were prepared using the magnetic probe method and sequenced as described above. The method gave reproducible high quality data which was assembled into current databases. Figure 3 shows a section of a read. The trace shows bases 125-375 from. a random M13 sub-clone containing a 1-2kb insert. From the sequence data available, it is clear that the procedure is reproducible and not sensitive to fluctuations in template or bead concentrations. Few sub-clones failed to give sequence and overall the results were comparable to the standard PEG/phenol method.
Re-use of Beads
After the preparation of a batch of DNA samples, beads may be re-used as outlined below.
Beads were collected and pooled in a 1.5ml eppendorf tube. The supernatant was removed and the beads were resuspended in 1ml reuse buffer (0.15M NaOH, 0.001% Tween 20) for 1 minute. The supernatant was removed and the procedure repeated. Finally the beads were washed once in storage buffer and taken up in half the original volume of storage buffer (PBS pH 7.5, 0.1% BSA). Beads were then stored at 4°C.
As will be apparent, the preparation steps described above can conveniently be carried out using automated apparatus, for example as described in GB9212164.9 (co-pending international application No PCT/GB93/ ).
In an alternative method, 50 ul of hydridisation buffer is added to each well, instead of 20 ul as described above, and the volume of beads added to the well reduced slightly to compensate. This enables sufficient template DNA to be obtained from just 200 ul of M13 supernatant (instead of 400 ul as described above). Thus 1 microtitre plate well is sufficient for the analysis of 1 clone, whereas previously 2 wells were required to obtain sufficient template DNA from each clone analysed. As a result, twice as many clones can be studied per microtitre plate than was the case previously.
A preferred feature of the method of preparing DNA is to bring about magnetic attraction for the magnetic beads by the use of a "dot magnet". This is a device with the dimensions of a typical microtitre assay plate (generally 130 mm by 85 mm) which comprises an array of rare earth magnets. Preferably the dot magnet comprises an array of 96 such rare earth magnets which are positioned in a matrix 8 x 12 and are separated by about 9mm from each nearest neighbour (ie. substantially the same spacing as that between the wells of a microtitre plate) thus when the sides of the dot magnet are aligned with the sides of a typical microtitre plate, each rare earth magnet is positioned beneath a well in the microtitre plate.
SEQUENCE LISTING
(1) GENERAL INFORMATION: (i) APPLICANT:
(A NAME: Medical Research Council (B STREET: 20 Park Crescent (C CITY: London (E COUNTRY: United Kingdom (F POSTAL CODE (ZIP): WIN 4AL (G TELEPHONE: (071) 636 5422 (H TELEFAX: (071) 323 1331
(A NAME: Hawkins, Trevor L. , (B STREET: Promega Corp., 2800 Woods Hollow Road (C CITY: Madison (D STATE: Wisconsin (E COUNTRY: U.S.A. (F POSTAL CODE (ZIP): 53711-5399
(ii) TITLE OF INVENTION: Preparation of Nucleic Acids (iii) NUMBER OF SEQUENCES: 1
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25 (EPO)
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iii) ANTI-SENSE: NO
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TATCGGCCTC AGGAAGATCG CACTCCAGCC AGCAAAAAAA 40
SUBSTITUTESHEET

Claims

Claims
1. A composition comprising magnetic particles, each bearing a plurality of oligonucleotides, each oligonucleotide comprising a sequence, acting as a probe, which is complementary to a sequence under investigation, and further comprising a sequence which is non- complementary to the sequence under investigation.
2. A composition according to claim 1, wherein the magnetic particle comprises a bead of l-5um in diameter.
3. A composition according to claim 1 or 2, wherein the oligonucleotides are single stranded DNA.
4. A composition according to any of claims 1, 2 or 3, wherein the complementrary probe sequence of the oligonucleotides is in the range 25-45 bases long.
5. A composition according to any one of the preceding claims, wherein the complementary probe sequence is complementary to M13.
6. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonucleotides is in the range 5-15 bases long.
7. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonuleotides is biotinylated.
8. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonucleotides acts as a linker between the magnetic particle and the complementary probe sequence of the oligonucleotides.
9. A composition according to any one of the preceding claims, wherein the non-complementary sequence of the oligonucleotides is at the 3' end of the complementary probe sequence.
10. A method of making the composition of any one of claims 1-9, comprising attaching magnetic particles to an oligonucleotide comprising a complementary probe sequence and further comprising a non-complementary sequence.
11. A method of separating a nucleic acid sequence from a sample, comprising: contacting a complex sample possibly including the sequence of interest with the composition according to any one of claims 1-9; allowing the sequence of interest, if present, to associate with the composition by means of hybridisation with the complementary probe sequence; and separating the particles and any bound nucleic acid sequences from the rest of the sample by magnetic attraction.
12. A method according to claim 11, wherein the sequence of interest comprises a DNA sequence to be determined.
13. A method of preparing a nucleic acid sequence of interest from a complex sample, comprising: causing lysis of nucleic acid-containing entities by the action of heat in the presence of a suitable detergent; adding magnetic particles attached to a probe complementary to at least part of the sequence of interest (hereinafter "particle/probe complex"), together with hydridisation buffer containing a polymer to cause an increase in the effective nucleic acid concentration; allowing the sequence of interest to hybridise to the complementary probe; and then separating the particle/probe complex and any sequences hybridised thereto from the rest of the sample by magnetic attraction.
14. A method according to claim 13, wherein the detergent is SDS.
15. A method according to claim 13 or 14, wherein the nucleic acid-containing entity is a bacteriophage.
16. A method according to any one of claims 13-15, wherein the nucleic acid is DNA.
17. A method according to any one of claims 13-16 wherein the particle/probe complex is comprised within a composition in accordance with any one of claims 1-9.
18. A method of preparing a nucleic acid by means of a sequence-specific purification step performed in a microtitre plate.
PCT/GB1993/001223 1992-06-09 1993-06-09 Preparation of nucleic acids WO1993025709A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43440/93A AU4344093A (en) 1992-06-09 1993-06-09 Preparation of nucleic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929212164A GB9212164D0 (en) 1992-06-09 1992-06-09 Preparation of nucleic acids
GB9212164.9 1992-06-09

Publications (1)

Publication Number Publication Date
WO1993025709A1 true WO1993025709A1 (en) 1993-12-23

Family

ID=10716759

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1993/001223 WO1993025709A1 (en) 1992-06-09 1993-06-09 Preparation of nucleic acids
PCT/GB1993/001222 WO1993025912A2 (en) 1992-06-09 1993-06-09 Automated preparation of nucleic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001222 WO1993025912A2 (en) 1992-06-09 1993-06-09 Automated preparation of nucleic acids

Country Status (3)

Country Link
AU (2) AU4343993A (en)
GB (1) GB9212164D0 (en)
WO (2) WO1993025709A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009379A1 (en) * 1994-09-20 1996-03-28 Whitehead Institute For Biomedical Research Dna purification and isolation using a solid phase
US5683875A (en) * 1995-05-04 1997-11-04 Hewlett-Packard Company Method for detecting a target nucleic acid analyte in a sample
DE19801730A1 (en) * 1998-01-19 1999-07-22 Fraunhofer Ges Forschung Analyzing cell contents, especially nucleic acids, useful for medical diagnostics
DE19943374A1 (en) * 1999-09-10 2001-03-29 Max Planck Gesellschaft Method for binding nucleic acids to a solid phase
WO2001051665A2 (en) * 2000-01-13 2001-07-19 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2001073123A2 (en) * 2000-03-28 2001-10-04 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2002018643A2 (en) * 2000-08-11 2002-03-07 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2002046472A2 (en) * 2000-12-08 2002-06-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US6602669B2 (en) 2000-07-11 2003-08-05 Northwestern University Method of detection by enhancement of silver staining
US6645721B2 (en) 1996-07-29 2003-11-11 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6773884B2 (en) 1996-07-29 2004-08-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6812334B1 (en) 1996-07-29 2004-11-02 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6977178B2 (en) 2000-09-06 2005-12-20 Transnetyx, Inc. System and method for transgenic and targeted mutagenesis screening
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2006059386A1 (en) * 2004-12-02 2006-06-08 National Institute Of Agrobiological Sciences Method of isolating double-stranded dna containing simple sequence repeats
US7186814B2 (en) 2001-11-09 2007-03-06 Nanosphere, Inc. Bioconjugate-nanoparticle probes
US7253277B2 (en) 2002-07-02 2007-08-07 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
US7527929B2 (en) 2004-07-30 2009-05-05 Agencourt Bioscience Corporation Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4409436A1 (en) * 1994-03-19 1995-09-21 Boehringer Mannheim Gmbh Process for processing nucleic acids
DE4421058A1 (en) 1994-06-16 1995-12-21 Boehringer Mannheim Gmbh Process for the magnetic separation of liquid components
WO1996011406A1 (en) * 1994-10-07 1996-04-18 Flinders Technologies Pty. Ltd. Apparatus and method for storage, purification or reaction and processing of a biopolymer
US6919175B1 (en) 1995-04-01 2005-07-19 Roche Diagnostics Gmbh System for releasing and isolating nucleic acids
DE19512368A1 (en) * 1995-04-01 1996-10-02 Boehringer Mannheim Gmbh Nucleic acid release and isolation system
GB9525794D0 (en) * 1995-12-18 1996-02-21 Hale Alan Biotechnological process
US5779985A (en) * 1995-12-18 1998-07-14 Solid Phase Sciences Corporation Reaction plenum
US6277332B1 (en) 1995-12-18 2001-08-21 Solid Phase Sciences Corporation Reaction plenum with magnetic separation and/or ultrasonic agitation
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
FR2760844B1 (en) * 1997-03-17 1999-05-21 Genethon Ii DEVICE AND METHOD FOR AUTOMATIC ANALYSIS OF SAMPLES ON GELS
US5912129A (en) * 1998-03-05 1999-06-15 Vinayagamoorthy; Thuraiayah Multi-zone polymerase/ligase chain reaction
AU2006230730B2 (en) * 1998-05-01 2009-03-05 Gen-Probe Incorporated Multiple ring assembly for providing specimen to reaction receptacles within an automated analyzer
AU2003271382B2 (en) * 1998-05-01 2006-07-20 Gen-Probe Incorporated Automated Diagnostic Analyzer and Method
US8337753B2 (en) 1998-05-01 2012-12-25 Gen-Probe Incorporated Temperature-controlled incubator having a receptacle mixing mechanism
DE10011555T1 (en) * 1998-05-01 2012-02-02 Gen-Probe Inc. Automatic diagnostic analyzer and method
DE19854003A1 (en) * 1998-11-18 2000-05-25 Jenoptik Jena Gmbh Simultaneous magnetic particle handling in a two-dimensional arrangement
WO2001002554A2 (en) * 1999-07-05 2001-01-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for high-throughput selection of interacting molecules
DE19954840A1 (en) * 1999-11-09 2001-05-17 Biopsytec Gmbh Device for the preparation of biological samples for DNA analysis
JP2002022752A (en) * 2000-07-13 2002-01-23 Suzuki Motor Corp Specimen testing device
DE10065148B4 (en) * 2000-12-22 2004-01-22 Institut für Physikalische Hochtechnologie e.V. Magnetic gripping-holding arrangement
US8615368B2 (en) 2005-03-10 2013-12-24 Gen-Probe Incorporated Method for determining the amount of an analyte in a sample
CN103589627B (en) 2010-07-23 2015-11-18 贝克曼考尔特公司 For carrying out heat circulator module and the system of PCR in real time in PCR reaction vessel
US9046507B2 (en) 2010-07-29 2015-06-02 Gen-Probe Incorporated Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure
EP2678664B1 (en) 2011-02-24 2019-08-07 Gen-Probe Incorporated Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector
US9910054B2 (en) 2011-11-07 2018-03-06 Beckman Coulter, Inc. System and method for processing samples
EP2776844B1 (en) 2011-11-07 2020-09-30 Beckman Coulter, Inc. Specimen container detection
CN104105969B (en) 2011-11-07 2016-10-12 贝克曼考尔特公司 Centrifuge system and workflow
WO2013070748A1 (en) 2011-11-07 2013-05-16 Beckman Coulter, Inc. Magnetic damping for specimen transport system
ES2844324T3 (en) 2011-11-07 2021-07-21 Beckman Coulter Inc Robotic arm
CN104040357B (en) 2011-11-07 2016-11-23 贝克曼考尔特公司 Halver system and workflow

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005815A1 (en) * 1985-03-25 1986-10-09 Genetics International Inc. Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences.
WO1990006045A2 (en) * 1988-11-21 1990-06-14 Dynal As Nucleic acid probes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU596987B2 (en) * 1985-08-30 1990-05-24 Tosoh Corporation Automated immunoassay analyser
FR2633310A1 (en) * 1988-06-24 1989-12-29 Pasteur Institut Apparatus for the repeated automatic execution of a thermal cycle in several successive stages, especially for the enzymatic amplification of nucleic acid sequences
GB8816982D0 (en) * 1988-07-16 1988-08-17 Probus Biomedical Ltd Bio-fluid assay apparatus
CA2031912A1 (en) * 1989-12-22 1991-06-23 Robert Fred Pfost Heated cover device
WO1991016675A1 (en) * 1990-04-06 1991-10-31 Applied Biosystems, Inc. Automated molecular biology laboratory
WO1992005443A1 (en) * 1990-09-15 1992-04-02 Medical Research Council Reagent separation
EP0479448A3 (en) * 1990-10-02 1992-12-23 Beckman Instruments, Inc. Magnetic separation device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005815A1 (en) * 1985-03-25 1986-10-09 Genetics International Inc. Nucleic acid sequences attached to materials sensitive to magnetic fields, and methods of assay and apparatus using such attached sequences.
WO1990006045A2 (en) * 1988-11-21 1990-06-14 Dynal As Nucleic acid probes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY vol. 201, February 1992, NEW YORK US pages 166 - 169 ALDERTON ET AL. 'Magnetic bead purification of M13 DNA sequencing templates' cited in the application *

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009379A1 (en) * 1994-09-20 1996-03-28 Whitehead Institute For Biomedical Research Dna purification and isolation using a solid phase
US5705628A (en) * 1994-09-20 1998-01-06 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles
US5898071A (en) * 1994-09-20 1999-04-27 Whitehead Institute For Biomedical Research DNA purification and isolation using magnetic particles
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US5683875A (en) * 1995-05-04 1997-11-04 Hewlett-Packard Company Method for detecting a target nucleic acid analyte in a sample
US6986989B2 (en) 1996-07-29 2006-01-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6682895B2 (en) 1996-07-29 2004-01-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6902895B2 (en) 1996-07-29 2005-06-07 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6812334B1 (en) 1996-07-29 2004-11-02 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6777186B2 (en) 1996-07-29 2004-08-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6773884B2 (en) 1996-07-29 2004-08-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7259252B2 (en) 1996-07-29 2007-08-21 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6582921B2 (en) 1996-07-29 2003-06-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses thereof
US7250499B2 (en) 1996-07-29 2007-07-31 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6610491B2 (en) 1996-07-29 2003-08-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7208587B2 (en) 1996-07-29 2007-04-24 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7098320B1 (en) 1996-07-29 2006-08-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6645721B2 (en) 1996-07-29 2003-11-11 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6673548B2 (en) 1996-07-29 2004-01-06 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6677122B2 (en) 1996-07-29 2004-01-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6903207B2 (en) 1996-07-29 2005-06-07 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6709825B2 (en) 1996-07-29 2004-03-23 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6720147B2 (en) 1996-07-29 2004-04-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6720411B2 (en) 1996-07-29 2004-04-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6730269B2 (en) 1996-07-29 2004-05-04 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6740491B2 (en) 1996-07-29 2004-05-25 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6750016B2 (en) 1996-07-29 2004-06-15 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6759199B2 (en) 1996-07-29 2004-07-06 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6767702B2 (en) 1996-07-29 2004-07-27 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6984491B2 (en) 1996-07-29 2006-01-10 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6969761B2 (en) 1996-07-29 2005-11-29 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6962786B2 (en) 1996-07-29 2005-11-08 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6818753B2 (en) 1996-07-29 2004-11-16 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6828432B2 (en) 1996-07-29 2004-12-07 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6861221B2 (en) 1996-07-29 2005-03-01 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6878814B2 (en) 1996-07-29 2005-04-12 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
DE19801730A1 (en) * 1998-01-19 1999-07-22 Fraunhofer Ges Forschung Analyzing cell contents, especially nucleic acids, useful for medical diagnostics
DE19943374A1 (en) * 1999-09-10 2001-03-29 Max Planck Gesellschaft Method for binding nucleic acids to a solid phase
WO2001051665A2 (en) * 2000-01-13 2001-07-19 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2001051665A3 (en) * 2000-01-13 2003-01-30 Nanosphere Inc Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2001073123A3 (en) * 2000-03-28 2003-02-06 Nanosphere Inc Nanoparticles having oligonucleotides attached thereto and uses therefor
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
WO2001073123A2 (en) * 2000-03-28 2001-10-04 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7323309B2 (en) 2000-03-28 2008-01-29 Northwestern University Bio-barcodes based on oligonucleotide-modified particles
US6602669B2 (en) 2000-07-11 2003-08-05 Northwestern University Method of detection by enhancement of silver staining
WO2002018643A3 (en) * 2000-08-11 2003-09-04 Nanosphere Inc Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2002018643A2 (en) * 2000-08-11 2002-03-07 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7011943B2 (en) 2000-09-06 2006-03-14 Transnetyx, Inc. Method for detecting a designated genetic sequence in murine genomic DNA
US6977178B2 (en) 2000-09-06 2005-12-20 Transnetyx, Inc. System and method for transgenic and targeted mutagenesis screening
US7282361B2 (en) 2000-09-06 2007-10-16 Transnetyx, Inc. Systems and methods for transgenic and targeted mutagenesis screening
WO2002046472A3 (en) * 2000-12-08 2003-09-04 Nanosphere Inc Nanoparticles having oligonucleotides attached thereto and uses therefor
WO2002046472A2 (en) * 2000-12-08 2002-06-13 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US7186814B2 (en) 2001-11-09 2007-03-06 Nanosphere, Inc. Bioconjugate-nanoparticle probes
US7253277B2 (en) 2002-07-02 2007-08-07 Nanosphere, Inc. Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes
US7527929B2 (en) 2004-07-30 2009-05-05 Agencourt Bioscience Corporation Methods of isolating nucleic acids using multifunctional group-coated solid phase carriers
WO2006059386A1 (en) * 2004-12-02 2006-06-08 National Institute Of Agrobiological Sciences Method of isolating double-stranded dna containing simple sequence repeats
JPWO2006059386A1 (en) * 2004-12-02 2008-06-05 独立行政法人農業生物資源研究所 Method for isolating double-stranded DNA containing simple repetitive sequence

Also Published As

Publication number Publication date
WO1993025912A2 (en) 1993-12-23
AU4343993A (en) 1994-01-04
GB9212164D0 (en) 1992-07-22
WO1993025912A3 (en) 1994-03-17
AU4344093A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
WO1993025709A1 (en) Preparation of nucleic acids
EP0901531B1 (en) Process for direct sequencing during template amplification
JP2839608B2 (en) Method for detecting nucleic acid sequence
US5830643A (en) Partially double-stranded oligonucleotide and method for forming oligonucleotide
EP0929693B1 (en) Multiplex polynucleotide capture methods and compositions
Tagle et al. Magnetic bead capture of expressed sequences encoded within large genomic segments
JP2701092B2 (en) Probe methods and compositions for detecting different DNA sequences
US5476769A (en) Method for assays of nucleic acid, a reagent combination and a kit therefor
AU708678B2 (en) Sequencing of nucleic acids
KR950003619B1 (en) Stand displacement amplification
WO1991011533A1 (en) Method for isolating primer extension products from template-directed dna polymerase reactions
JP2002512688A (en) Nucleic acid archiving
WO1993006243A1 (en) Dna cycle sequencing
US5554503A (en) Sample processing method for Mycobacterium tuberculosis
EP0595982A4 (en) Single step amplification and sequencing of nucleic acids
US5401632A (en) Triple helix purification and sequencing
WO1998008981A1 (en) METHODS FOR IDENTIFICATION AND ISOLATION OF SPECIFIC NUCLEOTIDE SEQUENCES IN cDNA AND GENOMIC DNA
US5770408A (en) Method for the amplification of a base sequence
US5972611A (en) Hybridization carrier and a process for preparing the same
EP0421469B1 (en) Method for separating a target oligonucleotide
EP1114185B1 (en) Method of isolating primer extension products with modular oligonucleotides
JP5128031B2 (en) Method for producing nucleic acid introduced with label using RecA protein
WO2022008649A1 (en) Spatial analysis of multiple targets in tissue samples
AU660484B2 (en) Single step amplification and sequencing of nucleic acids
CN115279918A (en) Novel nucleic acid template structure for sequencing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase